These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 36073856)
1. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development. Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856 [TBL] [Abstract][Full Text] [Related]
2. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Wang Q; Weisberg E; Zhao JJ Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925 [TBL] [Abstract][Full Text] [Related]
3. Hamartoma-like lesions in the mouse retina: an animal model of Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894 [No Abstract] [Full Text] [Related]
4. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis. Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654 [TBL] [Abstract][Full Text] [Related]
5. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F; J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809 [TBL] [Abstract][Full Text] [Related]
9. PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review. Rahmatinejad Z; Goshayeshi L; Bergquist R; Goshayeshi L; Golabpour A; Hoseini B Diagn Pathol; 2023 Apr; 18(1):43. PubMed ID: 37016356 [TBL] [Abstract][Full Text] [Related]
10. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951 [TBL] [Abstract][Full Text] [Related]
11. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation? Yehia L; Eng C Hum Mol Genet; 2020 Oct; 29(R2):R150-R157. PubMed ID: 32568377 [TBL] [Abstract][Full Text] [Related]
12. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922 [TBL] [Abstract][Full Text] [Related]
13. Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. Sloot YJE; Rabold K; Netea MG; Smit JWA; Hoogerbrugge N; Netea-Maier RT Oncogene; 2019 May; 38(19):3743-3755. PubMed ID: 30670777 [TBL] [Abstract][Full Text] [Related]
14. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Hollander MC; Blumenthal GM; Dennis PA Nat Rev Cancer; 2011 Apr; 11(4):289-301. PubMed ID: 21430697 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk and clinical implications for germline PTEN mutation carriers. Ngeow J; Sesock K; Eng C Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin treatment for a child with germline PTEN mutation. Marsh DJ; Trahair TN; Martin JL; Chee WY; Walker J; Kirk EP; Baxter RC; Marshall GM Nat Clin Pract Oncol; 2008 Jun; 5(6):357-61. PubMed ID: 18431376 [TBL] [Abstract][Full Text] [Related]
17. PTEN in Hereditary and Sporadic Cancer. Ngeow J; Eng C Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31570378 [TBL] [Abstract][Full Text] [Related]
18. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol. Ngeow J; Eng C Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771 [TBL] [Abstract][Full Text] [Related]
19. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations. Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080 [TBL] [Abstract][Full Text] [Related]
20. Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease. Torices L; Mingo J; Rodríguez-Escudero I; Fernández-Acero T; Luna S; Nunes-Xavier CE; López JI; Mercadillo F; Currás M; Urioste M; Molina M; Cid VJ; Pulido R Eur J Hum Genet; 2023 May; 31(5):568-577. PubMed ID: 36543932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]